Sular

Sular is a brand name of nisoldipine, approved by the FDA in the following formulation(s):

SULAR (nisoldipine - tablet, extended release; oral)

• 
  Manufacturer: SHIONOGI INC
  
  Approval date: January 2, 2008
  
  Strength(s): 17MG ^[RLD][AB], 25.5MG ^[AB], 34MG ^[RLD][AB], 8.5MG ^[RLD][AB]

Has a generic version of Sular been approved?

A generic version of Sular has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Sular and have been approved by the FDA:

nisoldipine tablet, extended release; oral

• 
  Manufacturer: MYLAN
  
  Approval date: January 26, 2011
  
  Strength(s): 17MG ^[AB], 25.5MG ^[AB], 34MG ^[AB], 8.5MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sular. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Tablets with controlled-rate release of active substances
  Patent 5,422,123
  Issued: June 6, 1995
  Inventor(s): Conte; Ubaldo & La Manna; Aldo & Colombo; Paolo
  Assignee(s): Jagotec AG
  Tablets with zero order controlled-rate of release of the active substances, consisting of a core of defined geometrical form containing the active substance, polymer substances which swell on contact with aqueous liquids and polymer substances with gelling properties, and a support applied to said core to partly cover its surface, the support consisting of polymer substances which are slowly soluble and/or slowly gellable in aqueous liquids, plasticizing substances, and possibly substances with an adjuvant function.
  
  Patent expiration dates:
  
  
  • June 6, 2012
    
    ✓ 
    Drug product
  
  



• 
  Controlled release pharmaceutical tablet having lenticular form
  Patent 5,626,874
  Issued: May 6, 1997
  Inventor(s): Conte; Ubaldo & La Manna; Aldo & Maggi; Lauretta
  Assignee(s): Ekita Investments N.V.
  Controlled release pharmaceutical tablet having a lenticular form consisting of three layers of which the central one or core (a) contains the active principle and the two outer layers or barriers (b) and (c) comprise gellable and/or erodible polymeric material, said barrier layers being equal or different among themselves for composition and/or thickness, while the central layer has a limited external annular surface exposed to the dissolution medium, through which the active principle is released.
  
  Patent expiration dates:
  
  
  • November 30, 2014
    
    ✓ 
    Drug product
  
  

See also...

• Sular Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Sular Consumer Information (Cerner Multum)
• Sular Advanced Consumer Information (Micromedex)
• Sular AHFS DI Monographs (ASHP)
• Nisoldipine Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Nisoldipine Consumer Information (Cerner Multum)
• Nisoldipine Advanced Consumer Information (Micromedex)
• Nisoldipine AHFS DI Monographs (ASHP)